Supriya Lifescience Ltd - Stock Valuation and Financial Performance

BSE: 543434 | NSE: SUPRIYA | Pharmaceuticals & Drugs | Small Cap

Supriya Lifescience Share Price

335.25 -4.60 -1.35%
as on 28-Mar'24 14:17

DeciZen - make an informed investing decision on Supriya Lifescience

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

Supriya Lifescience stock performance -

mw4me loader
P/E Ratio (SA):
22.72
Market Cap:
2,735.2 Cr.
52-wk low:
174
52-wk high:
393.7

Is Supriya Lifescience Ltd an attractive stock to invest in?

1. Is Supriya Lifescience Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Supriya Lifescience Ltd is a average quality company.

2. Is Supriya Lifescience Ltd undervalued or overvalued?

The key valuation ratios of Supriya Lifescience Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Supriya Lifescience Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Supriya Lifescience Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Supriya Lifescience:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Supriya Lifescience Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 12.9%11.3%8.6%7.4%7.5%25.1%37.8%44.4%31.7%13.6%-
Value Creation
Index
-0.1-0.2-0.4-0.5-0.50.81.72.21.30.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 113138171184213278312391530461554
Sales YoY Gr.-21.9%23.8%7.5%16%30.5%12.2%25.5%35.5%-13%-
Adj EPS 12.816.44.23.44.326.750.416.918.911.215
YoY Gr.-27.9%-74.3%-19.7%27.2%520.7%88.7%-66.5%11.7%-40.8%-
BVPS (₹) 49.464.223.827.637.364.1101.936.776.586.997.3
Adj Net
Profit
6.386.256.339.173.712415289.9120
Cash Flow from Ops. 0-6.313.527.327.848.911675.948.866.2-
Debt/CF from Ops. 0-15.89.65.14.71.80.70.90.40.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.9%16.7%13.9%-13%
Adj EPS -1.5%21%-39.5%-40.8%
BVPS6.5%18.4%-5.2%13.6%
Share Price - - - 90.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
22.323.615.611.312.552.660.759.234.313.716.2
Op. Profit
Mgn %
1312.511.99.310.323.831.744.340.427.931.2
Net Profit
Mgn %
5.55.83.62.7314.123.731.628.619.521.7
Debt to
Equity
2.63.23.73.52.410.60.300-
Working Cap
Days
205211217220174141166158140206140
Cash Conv.
Cycle
54657065542622195182114

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.94%

Sales growth is good in last 4 quarters at 16.71%

Return on Equity has declined versus last 3 years average to 16.20%

Net Profit has been subdued in last 3 years -39.46%

Latest Financials - Supriya Lifescience Ltd.

Standalone Consolidated
TTM EPS (₹) 15 -
TTM Sales (₹ Cr.) 554 -
BVPS (₹.) 97.3 -
Reserves (₹ Cr.) 767 -
P/BV 3.49 -
PE 22.72 -
From the Market
52 Week Low / High (₹) 174.00 / 393.70
All Time Low / High (₹) 170.05 / 601.90
Market Cap (₹ Cr.) 2,735
Equity (₹ Cr.) 16.1
Face Value (₹) 2
Industry PE 47.8

Management X-Ray of Supriya Lifescience:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Supriya Lifescience

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales113138171184213278312391530461
Operating Expenses 98121151166191213213218316332
Manufacturing Costs791216212724233450
Material Costs7288107123136147138128196181
Employee Cost 791013161926334956
Other Costs 12142115182125343746
Operating Profit 15172017226498173214128
Operating Profit Margin (%) 12.9%12.4%11.5%9.3%10.3%23.2%31.6%44.3%40.4%27.9%
Other Income 222798115810
Interest 67101211107443
Depreciation 224555671012
Exceptional Items 0000000000
Profit Before Tax 91088145796167207123
Tax 222261823445534
Profit After Tax 68669397312415290
PAT Margin (%) 5.5%6.0%3.3%3.1%4.1%14.2%23.6%31.6%28.6%19.5%
Adjusted EPS (₹)0.91.10.80.81.25.410.016.918.911.2
Dividend Payout Ratio (%)8%7%26%0%0%0%20%3%3%5%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 303741465594149269616699
Share Capital 551515151515151616
Reserves 263326314079135254600683
Minority Interest0000000000
Debt62991291401218579672117
Long Term Debt142034453582000
Short Term Debt47799595867777672117
Trade Payables31305041424449514964
Others Liabilities 7101215283059584940
Total Liabilities 130176231241245253336445735820

Fixed Assets

Gross Block537189989695114123223306
Accumulated Depreciation71014951016233345
Net Fixed Assets45617589918598100190262
CWIP 5112536343540794368
Investments 00000000025
Inventories303953383231497292116
Trade Receivables283542505360527411585
Cash Equivalents 457632289228158
Others Assets172428233241953166108
Total Assets 130176231241245253336445735820

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 0-614272849116764966
PBT 01088145796167207123
Adjustment 091316161310577
Changes in Working Capital 0-25-731-737-67-104-36
Tax Paid 0000-3-14-27-30-61-29
Cash Flow From Investing Activity 0-23-33-27-55-25-47-60-133
Capex 0-17-18-10-55-25-47-60-108
Net Investments 000000000-25
Others 0-6-15-17000000
Cash Flow From Financing Activity 03021-2-20-50-29-15150-3
Net Proceeds from Shares 001-100002000
Net Proceeds from Borrowing 05150-9-27-6-200
Interest Paid 0-7-10-13-11-10-6-4-4-3
Dividend Paid 000000-18-4-4-5
Others 0321612-1-130-4-425
Net Cash Flow 012-2346215139-70
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)29.5729.6117.215.0518.3853.1160.4259.1734.3413.66
ROCE (%)19.4315.8312.2711.4813.836.5249.6760.1243.3418.72
Asset Turnover Ratio1.040.980.920.830.981.291.221.110.66
PAT to CFO Conversion(x)0-0.752.334.53.111.261.590.610.320.73
Working Capital Days
Receivable Days69777686786457535971
Inventory Days92849085533541525174
Payable Days13912613513411110712314393114

Supriya Lifescience Ltd Stock News

Supriya Lifescience Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Supriya Lifescience on 28-Mar-2024 14:17 is ₹335.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 14:17 the market cap of Supriya Lifescience stood at ₹2,735.2.
The latest P/E ratio of Supriya Lifescience as of 28-Mar-2024 14:17 is 22.72.
The latest P/B ratio of Supriya Lifescience as of 28-Mar-2024 14:17 is 3.49.
The 52-week high of Supriya Lifescience is ₹393.7 and the 52-week low is ₹174.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Supriya Lifescience is ₹554.5 ( Cr.) .

About Supriya Lifescience Ltd

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

  • 2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
  • 2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
  • 2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
  • 2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
  • 2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
  • 2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
  • 2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

  • 2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
  • 2009: Started production of Ketamine Hydrochloride.
  • 2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
  • 2011: IDL granted for Chlorphenamine Maleate.
  • 2013: COFEPRIS and KFDA approval granted.
  • 2014: USFDA approval granted
  • 2014: IDL granted for Brompheniramine Maleate.
  • 2015: EUGMP and EDQM approval granted.
  • 2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
  • 2017: Second time USFDA approval granted.
  • 2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
  • 2020: Third time USFDA approval.
  • 2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
  • 2021: NMPA approval granted.
  • 2021: Health Canada approval.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.